| Vol. 14.23 – 14 June, 2022 |
| |
|
|
| Functional experiments using organoid models, explant cultures, and FACS-isolated RSPO2+ mesenchyme showed that RSPO2 was a critical niche cue that potentiated WNT signaling in bud tip progenitors to support their maintenance and multipotency. [Developmental Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators isolated and characterized two types of exosomes, conducted in vitro experiments to measure their effects on fibroblasts, and performed in vivo experiments to compare the effects on tendon-to-bone integration. [Materials Today Bio] |
|
|
|
| Researchers clarified the mechanism of long noncoding RNA ZBTB40-IT1 in directing human bone marrow-derived MSC (hBMSC) differentiation. hBMSCs underwent osteogenic and adipogenic induction, and an osteoporosis mouse model was established via ovariectomy. [Human Cell] |
| |
|
|
| The dominant-negative mutant of Cdc42 was used to explore the role of Cdc42 in activin B-induced adipose-derived MSC migration, proliferation, and secretion in vitro. [Stem Cell Research & Therapy] |
|
|
|
| Investigators treated DSS-induced colitis mice with adipose‐derived MSCs (ADMSCs) and revealed that ADMSCs alleviated colon inflammation by reducing the infiltration of M1 macrophages. [Frontiers in Immunology] |
|
|
|
| Scientists evaluated the anti-asthmatic effects of MSCs primed with Liproxstatin-1, a potent ferroptosis inhibitor. [Scientific Reports] |
|
|
|
|
| Due to the novelty of the field of using 3D culture MSCs-derived exosomes, examination of their properties and the results of their therapeutic application can increase the authors’ views of this field, as they discuss MSCs and their exosomes enhanced properties in spheroid culture. [Biomedicine & Pharmacotherapy] |
|
|
|
| Investigators discuss the pathological mechanisms following intracerebral hemorrhage and the therapeutic mechanisms of MSC-based therapy to unravel new cues for future therapeutic strategies. [Frontiers in Cellular Neuroscience] |
|
|
|
|
| Immunicum AB announced that it has been granted an orphan drug designation from the US FDA for ilixadencel in the treatment of GIST. A rare and difficult to treat subgroup of cancers referred to as soft tissue sarcoma. [Immunicum AB] |
|
|
|
|
| September 29 – 30, 2022 London, England, United Kingdom |
|
|
|
|
|
| Sanford Research – Sioux Falls, South Dakota, United States |
|
|
|
| Stem Cell Network – Ottawa, Ontario, Canada |
|
|
|
| China Medical University – Shenyang, China |
|
|
|
| Utrecht University – Utrecht, Netherlands |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|